Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
SAN MARINO, Calif., Jan. 19 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies (epeiusbiotech.com) announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., Santa Monica CA, January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At Dose Level I, three patients achieved stable disease with no tumor progression; and at Dose Level II, one patient had a 37 percent decrease in tumor size and five patients exhibited disease stabilization with no tumor progression.
Importantly, Rexin-G improved patient survival in a dose-dependent manner: At Dose Level I, median progression-free survival was 3 months, and median over-all survival was 5 months, while at Dose Level II, median progression-free survival was greater than 3 months, and median over-all survival was greater than 9 months.
By direct comparison with a prior low-dose Phase I safety study (Galanis et al. 2008), the new “effective doses” of Rexin-G nearly tripled the overall survival time. Thus, this current Phase I/II study defines a critical pharmacological “threshold” for Rexin-G bioactivity in the treatment of metastatic pancreatic cancer.
The present study confirms the overall safety of Rexin-G, and further demonstrates that Rexin-G monotherapy, at these defined dose levels, exhibits profound anti-tumor activity that prolongs both progression-free survival and over-all survival time in pancreatic cancer patients that had previously failed standard chemotherapy.
Rexin-G® is the world’s first and so far only targeted injectable genetic medicine that has been validated in the clinic (Nature Reviews/Genetics 2007). Injected intravenously, the targeted nanoparticles are designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body. The FDA has granted Orphan Drug Status for Rexin-G for the treatment of (i) pancreatic cancer, (ii) osteosarcoma, and (iii) soft tissue sarcoma, while the Philippine BFAD has granted accelerated approval of Rexin-G for the treatment of all solid tumors that are resistant to standard chemotherapy.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its tumor-targeted gene delivery systems. To learn more about ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.
More information online: www.epeiusbiotech.com.
All trademarks acknowledged.
News Source: Epeius Biotechnologies :: This press release was issued by Send2Press® and is Copyright © 2009 Neotrope® News Network – all rights reserved.
Repost This Press ReleaseMore Information:
Carly Zed Zander is the senior content editor for Send2Press Newswire, a service of Neotrope. Carly edits and checks format for all content being posted to our news network sites. She does not write press releases, she is in charge of formats for the sites and syndication elements. View the staff bio page (link bottom of all pages) for more information.
- Secret Sex Book Serialized on eNewsChannels
- Fourth of July Reminder for 50-Plus Americans: Think about Long-Term Care Independence
- Extreme Makeover: Home Edition Asks SimplyHome for Help
- New Hampshire Audi Dealer Inspired by Audi’s Plans to Unseat BMW as Luxury Leader
- Newest MINI Features Fewer Seats, More Thrills
Follow Send2Press on Social Media
Stay up to date with Send2Press on popular social portals.